You are here

GLP-1 agonist

Novo, Lilly set to dominate $71B GLP-1 drug market by 2032: J.P. Morgan

Novo, Lilly set to dominate $71B GLP-1 drug market by 2032: J.P. Morgan

Fierce Pharma

Flag link:

GLP-1 Drugs Show Promise in Alcohol, Opioid Use Disorders

GLP-1 Drugs Show Promise in Alcohol, Opioid Use Disorders

BioSpace

alcohol-use disorder

opioid use disorder

Flag link:

AstraZeneca drops another GLP-1 after phase 1 data bust market-beating diabetes hopes

AstraZeneca drops another GLP-1 after phase 1 data bust market-beating diabetes hopes

Fierce Biotech

type 2 diabetes

Flag link:

BIO: Can GLP-1s help you quit smoking or drinking? Lilly is looking into it—cautiously

BIO: Can GLP-1s help you quit smoking or drinking? Lilly is looking into it—cautiously

Fierce Biotech

smoking cessation

alcohol-use disorder

Flag link:

Lilly steps up its oral obesity push

Lilly steps up its oral obesity push

EP Vantage

Flag link:

Study: Type 2 Diabetes Treatments May Be More Effective When Combined

Study: Type 2 Diabetes Treatments May Be More Effective When Combined

BioSpace

type 2 diabetes

Flag link:

Highlights: 2019 Cardiometabolic Health Congress, Chicago IL

Highlights: 2019 Cardiometabolic Health Congress, Chicago IL

CP Wire

cardiometabolic health

chronic kidney disease

Flag link:

Highlights: 2019 Cardiometabolic Health Congress, Chicago IL

cardiometabolic health

chronic kidney disease

Flag link:

Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease

Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease

Fierce Biotech

Parkinson's Disease

Flag link:

Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?

Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?

Fierce Pharma

Flag link:

GI toxicity hits midstage Sanofi GLP-1 drug as patients drop out

GI toxicity hits midstage Sanofi GLP-1 drug as patients drop out

Fierce Biotech

clinical trials

Flag link:

GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk

GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk

Market Realist

Flag link:

GlaxoSmithKline GLP-1 Tanzeum meets its end, and it doesn't bode well for Sanofi, AstraZeneca: analyst

GlaxoSmithKline GLP-1 Tanzeum meets its end, and it doesn't bode well for Sanofi, AstraZeneca: analyst

Fierce Pharma

Flag link:

New Novo Nordisk Strategy Drops Oral Insulin, Expands Oral GLP-1

New Novo Nordisk Strategy Drops Oral Insulin, Expands Oral GLP-1

Seeking Alpha

Flag link:

Sanofi Should Be Thinking Longer Duration In GLP-1s

Sanofi Should Be Thinking Longer Duration In GLP-1s

Seeking Alpha

Flag link:

Diabetes sales rocket toward $60B, with Novo and Lilly's GLP-1s first in line for growth

Diabetes sales rocket toward $60B, with Novo and Lilly's GLP-1s first in line for growth

Fierce Pharma

Flag link:

Novo Nordisk notches another phase 3 success for GLP-1 drug

Novo Nordisk notches another phase 3 success for GLP-1 drug

BioPharma Dive

Flag link:

Novo Nordisk's First Diabetes Pill Could Be A $10-20 Billion Super-Blockbuster

Novo Nordisk's First Diabetes Pill Could Be A $10-20 Billion Super-Blockbuster

Seeking Alpha

Flag link:

Sanofi, Hanmi seal diabetes license deal for up to $4.2 bln

Sanofi, Hanmi seal diabetes license deal for up to $4.2 bln

Yahoo/Reuters

Flag link:

Victoza tops Sanofi's Lyxumia in trial, adding to Novo's GLP-1 arsenal

Victoza tops Sanofi's Lyxumia in trial, adding to Novo's GLP-1 arsenal

Fierce Pharma

Flag link:

Pages